Expertise in
24
conditions

Dr. Michael Savona

Hematology
Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
24
conditions
Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, 
Nashville, TN 

Overview

Michael Savona is a Hematologist practicing medicine in Nashville, Tennessee.

Dr. Savona is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelofibrosis, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 191 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in TX

Hospital Affiliations

Vanderbilt University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
Enrollment Status: Recruiting
Publish Date: April 30, 2026
Intervention Type: Drug
Study Drugs: Azacitidine, Cedazuridine
Study Phase: Phase 2/Phase 3
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
Enrollment Status: Completed
Publish Date: May 19, 2026
Intervention Type: Drug
Study Drugs: TGR-1202 PI3K Delta Inhibitor, Ruxolitinib
Study Phase: Phase 1
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Decitabine, Cedazuridine, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drugs: SEL24, MEN1703
Study Phase: Phase 1/Phase 2
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Procedure
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Enrollment Status: Completed
Publish Date: October 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

191 Total Publications

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
Journal: The New England journal of medicine
Published: June 03, 2026
Similar Doctors
Expertise in
43
conditions
Dr. Ian Flinn
Hematology
Expertise in
43
conditions
Dr. Ian Flinn
Hematology
Referral may be required

Tennessee Oncology Pharmacy Dispensing

250 25th Ave N Ste 412, 
Nashville, TN 
 (0.9 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ian Flinn is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
18
conditions
Dr. Brian Rini
Hematology
Expertise in
18
conditions
Dr. Brian Rini
Hematology
Referral may be required

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brian Rini is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Rini is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy.

Expertise in
41
conditions
Dr. Jesus Berdeja
Hematology
Expertise in
41
conditions
Dr. Jesus Berdeja
Hematology
Referral may be required

Tennessee Oncology Pharmacy Dispensing

250 25th Ave N Ste 412, 
Nashville, TN 
 (0.9 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jesus Berdeja is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Berdeja is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Michael Savona

How do I make an appointment with Dr. Michael Savona?

You can book an appointment with Dr. Michael Savona by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Savona a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Savona is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Savona specialize in?

While Dr. Michael Savona is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Michael Savona participate in research or clinical trials?

Yes. Dr. Michael Savona has published 191 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Michael Savona's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Savona accept my insurance?

Dr. Michael Savona accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Savona's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile